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The management of classical Hodgkin’s lymphoma (CHL) is a success story of modern multi-agent haemato-oncology. Prior
to the middle of the twentieth century CHL was fatal in the majority of cases. Introduction of single agent radiotherapy (RT)
demonstratedfortheﬁrsttimethatthesepatientscouldbe cured. Developmentsinchemotherapyincludingthemechlorethamine,
vincristine, procarbazine and prednisolone (MOPP) and Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) regimens
haveresulted incureratesofover80%.Eveninrelapse, CHLpatientscanbesalvagedwithhighdosechemotherapyandautologous
haematopoietic stem cell transplantation (ASCT). Challenges remain, however, in ﬁnding new strategies to manage the small
number of patients who continue to relapse or progress. In addition, the young age of many Hodgkin’s patients forces diﬃcult
decisions in balancing the beneﬁt of early disease control against the survival disadvantage of late toxicity. In this article we aim to
summarisepast trials, deﬁne the current standard of care and appraise future developments in the management of CHL.
1.Introduction
The management of classical Hodgkin’s lymphoma (CHL)
is a success story of modern multiagent haemato-oncology.
Prior to the middle of the twentieth century CHL was fatal
in the majority of cases. Introduction of single-agent radio-
therapy (RT) demonstrated for the ﬁrst time that these
patients could be cured. Developments in chemotherapy
including the mechlorethamine, vincristine, procarbazine,
and prednisolone (MOPP) and adriamycin, bleomycin, vin-
blastine, and dacarbazine (ABVD) regimens have resulted in
cure rates of over 80%. Even in relapse, CHL patients can
be salvaged with high-dose chemotherapy and autologous
haematopoietic stem cell transplantation (ASCT).
Challenges remain, however, in ﬁnding new strategies
to manage the small number of patients who continue to
relapse or progress. In addition, the young age of many
H o d g k i n ’ sp a t i e n t sf o r c e sd i ﬃcult decisions in balancing the
beneﬁt of early disease control against the survival disadvan-
tage of late toxicity. In this paper we aim to summarise past
trials, deﬁne the current standard of care,and appraise future
developments in the management of CHL.
2.ClinicalRiskStratiﬁcation
Accurateassessment of prognosis is essential to direct appro-
priate therapy at the earliest opportunity. Current practice
is to deﬁne risk groups on adverse presenting clinical risk
factors such as disease stage, presence of B symptoms, bulky
disease, and patient age. Using these parameters, research
groups have deﬁned three treatment groups requiring dif-
ferent treatment intensities (Table 1). In addition, clinical
markers can be used to create an International Prognostic
Score (IPS) for advanced stage disease (Table 2)[ 1].
3.Managementof EarlyStageFavourableCHL
Limited stage CHL is a highly curable disease. In 1989
an international workshop and symposium met in Paris
to review the outcomes of CHL cases treated between the
1960s and 1987. More than 9000 early stage patients were
reviewed from a total of 14702 cases. Long-term mortality
was 22%; in the ﬁrst decade this was mainly due to
relapse, but after 13 years of followup deaths from second
malignancies and cardiovascular disease were relatively high.2 Advances in Hematology
Table 1: Risk groups in CHL: clinical criteria used by European
Organisation for Research and Treatment of Cancer (EORTC)
and German Hodgkin Lymphoma Study Group (GHSG) to deﬁne
treatment groups. Abbreviations: ESR, erythrocyte sedimentation
rate(mm/h);CS,clinicalstage;MTR,mediastinum-to-thoraxratio.
EORTC GHSG
Risk factor (RF)
(1) Age ≥ 50y (1) Large mediastinal
mass
(2) B symptoms +
ESR:
(2) Extranodal
disease/massive
spleen
(a) No symptoms
+E S R≥ 50 (3) ESR
(b) Symptoms +
ESR ≥ 30
(a) >50 without B
symptoms
(3) >3 nodal areas (b) >30 with B
symptoms
(4) MTR ≥ 0.35 (4) >3 involved nodal
regions
Early stage
without RFs CS I-II CS I-II
Early stage
unfavourable/
intermediate stage
CS I-II with one RF CS I or IIA with RF
CS IIB with RF 3 or 4
Advanced stage CS III-IV CS IIB with RF 1 or 2
CS III or IV
Table 2: Outcome for advanced Hodgkin’s lymphoma based on
International Prognostic Score. Risk factors: age >45y, stage IV,
male sex, white cell count >15 × 10
9/L, lymphocyte count <0.6 ×
10
9/L/8%, albumin <40g/L, and haemoglobin <10.5g/dL.
5y e a r
Number of factors Freedom from
progression (%)
Overall survival
(%)
08 4 8 9
17 7 9 0
26 7 8 1
36 0 7 8
45 1 6 1
5o rm o r e 4 2 5 6
The most important risk factors for late mortality were older
age and exposure to wide-ﬁeld radiotherapy or MOPP-like
chemotherapy [2]. This was the ﬁrst acknowledgment that
late eﬀects of treatment could aﬀect long-term survival; the
relatively young age of CHL patients results in late eﬀects
having a disproportionate impact. Trials in early stage CHL
have therefore tried to progressively reduce exposure to toxic
agents.
Monotherapy with radiotherapy (RT) is an eﬀective
treatment in early stage CHL, but wide radiation ﬁelds and
high doses are associated with considerable late toxicity, and
it is no longer standard practice. Major trials in early stage
favourableCHL(Table 3)haveinvestigatedreducingRTﬁeld
size and dose and incorporating abbreviated chemotherapy
regimens into combined modality treatment (CMT).
3.1. Combined Modality Therapy. An early study by the
Southwest Oncology Group compared subtotal lymphoid
irradiation (STLI) with CMT (STLI plus adriamycin/vin-
blastine; the least toxic agents of the ABVD regimen used
in advanced stage CHL) [3]. The trial was closed early after
a signiﬁcant beneﬁt in failure-free survival (FFS) emerged
in the CMT arm. Overall survival (OS) was not diﬀerent at
3 years. Haematological toxicity was signiﬁcantly higher in
the CMT group. The German Hodgkin Lymphoma Study
Group (GHSG) compared extended-ﬁeld (EF) RT with
CMT (2ABVD and EF RT) in the HD7 trial [4]. Seven-
year followup showed improved freedom from treatment
failure (FFTF) in the CMT arm at the expense of more
haematological toxicity, but no diﬀerence in OS or second
malignancy. The EORTC H7F trial compared STLI to CMT
consisting of 6 EBVP (epirubicin, bleomycin, vinblastine,
and prednisolone) and involved-ﬁeld (IF) RT [5]. EBVP was
thought to confer less cardiac toxicity and nausea compared
toABVD.Ten-yearevent-freesurvival(EFS)wasbetterinthe
CMT arm with a very low rate of secondary malignancies,
butOSwasagainnotdiﬀerent.Soonafter, theEORTC/GELA
H8F trial demonstrated that both improved 10-year EFS and
OS when comparing CMT (3MOPP/ABV and IF RT) to
STLI monotherapy [6]. The Milan group directly compared
radiation ﬁelds within ABVD-based CMT in a single centre
study of STLI versus IF RT. With 12-year followup there
was no diﬀerence in disease progression or survival, but the
study was not powered to detect noninferiority of IF RT to
STLI [7].
3.2. Chemotherapy as Monotherapy. The consensus opinion
from these trials was that CMT provides better disease con-
trol than radiotherapy alone and that reduction in radio-
therapy to IF RT was feasible. Two to four cycles of ABVD
wereestablishedasthechemotherapyregimenofchoice.This
led other groups to question the beneﬁt of RT and study
chemotherapy monotherapy.
The NCI-C/ECOG H6 study combined favourable and
unfavourable (age >40, ESR >50mm/h, >3 sites of disease,
mixed cellularity/lymphocyte-deplete histology) early stage
CHL into groups receiving some radiotherapy or chemother-
apy alone [8]. One hundred and twenty three favourable risk
patientswere randomised to STLIor 4–6cyclesofABVD. No
diﬀerences in 5-year freedom from progression (FFP) or OS
were seen. A single-centre study by Straus et al. randomised
152 patients to CMT (6ABVD + RT) or 6 cycles of ABVD
alone [9]. Five-year PFS and OS were not diﬀerent, but the
study was powered to detect an expected beneﬁt of over
20% for CMT rather than equivalence between the two
therapies.Asystematic reviewbyHerbstetal.showed beneﬁt
in tumour control and OS from CMT [10].
3.3. Current Standard of Care and Future Directions. The
GHSG HD10 trial has deﬁned the current standard of care
forpatientswithearlystage,favourableHL[11].Usinga2×2
factorial designthegrouprandomised 1370patientstoeither
2 or 4 cycles of ABVD followed by either 20 or 30 Gray
( G y )I FR T .F i v e - y e a rr e s u l t ss h o wn od i ﬀerence in disease
control between the two groups. There was less acute toxicityAdvances in Hematology 3
and fewer acute toxic deaths with 2 cycles of chemotherapy
comparedwith4and lesstoxicity(e.g.,mucositis,dysphagia)
with 20Gy compared with 30Gy. The EORTC/GELA/IIL
intergroup have an ongoing trial of 3 cycles of ABVD with
IF RT. We believe, however, the current standard of care for
early stage favourable CHL to be 2 cycles of ABVD followed
by 20Gy IF RT.
OngoingtrialsinearlyfavourableCHLarelookingatfur-
ther reducing toxicity. The GHSG HD13 trial is investigating
whether individual chemotherapeutic agents can be omitted
from the ABVD regimen by comparing 2 cycles of ABVD,
AV, ABV, or AVD followed by 30Gy IF RT. Preliminary
reports suggest a poorer outcome in patients not receiving
dacarbazine. The EORTC H9F trial investigates the optimal
dose of IF RT by randomising patients to 6 cycles of EBVP
followed by 0, 20, or 36Gy of IF RT. Until the results of
H9F study are available a reasonable approach is 20Gy of
radiotherapy, in light of the GHSG HD10 results mentioned
above. Future studies will deﬁne whether functional imaging
can eliminate the need for radiotherapy altogether in early
stage disease. The UK RAPID trial is a phase III multicentre
randomised study assessing the role of FDG-PET imaging
in patients with clinical stage IA/IIA Hodgkin’s lymphoma.
Patients who are PET negative after 3 cycles of ABVD
are randomised to receive either involved-ﬁeld RT (Arm
A) or no further treatment (Arm B). Individuals who are
PET positive will receive a further (4th) cycle of ABVD
followed by involved-ﬁeld radiotherapy. The GHSG HD16
trial randomises patients to either 2 cycles of ABVD plus
20Gy IF RT and end-of-treatment PET or 2ABVD followed
by RT in PET+ and observation in PET−.
4.ManagementofEarlyStage
Unfavourable CHL
It is clear that certain risk factors (Table 1) confer additional
risk to early stage CHL that requires more intensive CMT
treatment. Trials have sought to ﬁnd the combination of
chemotherapy and radiation exposure that provide optimal
disease control whilst limiting toxicity (Table 4).
CMT is the established treatment for early stage
unfavourable CHL. The outcome of the Canadian HD6 trial
(above)wasdominatedbytheunfavourablegroupbeneﬁting
from CMT (2ABVD plus STLI) compared to 4–6 cycles of
ABVD alone (5-year FFP 95% versus 88%, P = .004) [8].
ABVD-based CMT has been shown to be superior to MOPP
or EBVP in two well-conducted randomised controlled trials
in this setting [5, 12]. The EORTC H8U trial tested 4
versus 6 cycles of MOPP/ABV and 36Gy IF RT versus STLI
demonstrating no diﬀerence [6]. The GHSG HD8 trial also
looked at reducing radiation ﬁeld from extended-ﬁeld (EF)
to IF RT following 4 cycles of ABVD-based chemotherapy
[13]. In 1064 patients 5-year freedom from treatment failure
(FFTF) and OS were equivalent, with less grade III-IV
haematological toxicity in the IF RT arm.
4.1. Current Standard of Care and Future Directions. The
results of the EORTC H8U and GHSG HD8 studies establish
4 cycles of ABVD-based chemotherapy followed by 36–
40Gy IF RT as the current standard of care in early stage
unfavourable CHL.
Ongoing trials are looking at reducing exposure to radia-
tion and testing more intensive chemotherapy regimens. The
EORTCH10trial iscomparingCMTtochemotherapyalone.
The GHSG HD 11 trial has a 2×2d e s i g nc o m p a r i n g4c y c l e s
of ABVD to BEACOPP (bleomycin, etoposide, adriamycin,
vincristine, procarbazine, and prednisolone) followed by IF
RT at either 20 or 30Gy. Interim results suggest inferiority
of 20Gy compared to 30Gy. The EORTC H9U trial also
looks at increasing chemotherapy comparing 4 and 6
cycles of ABVD and 4 cycles of BEACOPP all followed by
30Gy IF RT. The GHSG HD 14 trial compares 4ABVD
or 2BEACOPP+2ABVD followed by 30Gy IF RT. Interim
results show a 6% superior PFS in the BEACOPP arm. With
increasinginterestintheprognosticvalueofinterimpositron
emission tomography (PET) scanning (see later), the H10
EORTC/GELA/IIL intergroup study is assessing if a negative
PET scan after two cycles of chemotherapy can be used to
de-escalate from 6 to 4 cycles of ABVD. The GHSG HD17
trial treats patients with 2 cycles of escalated BEACOPP and
2ABVD followed by a randomisation based on PET if PET+
patients are randomised to 30Gy RT by either IF or involved
node and if PET− patients are randomised to observation or
30Gy IF RT.
5.Managementof AdvancedStageHL
In the 1970s MOPP chemotherapy became the standard of
care in advanced CHL with 20-year OS of 48%. Toxicity
was high, however, with 100% infertility in men and a 2%
rate of secondary leukaemia [14]. Through the 1980s and
1990s ABVD-based regimens were compared to MOPP,
although the two regimens were never tested head-to-head
in a randomised controlled trial (Table 5). In summary,
alternating MOPP/ABVD and ABVD was equivalent and
both were superior to MOPP alone [15, 16]. Alternating
MOPP/ABVD was equivalent to MOPP/ABVD [17]o r
MOPP/ABV hybrid [18], but there was more toxicity in the
MOPP/ABV hybrid arm. Duggan found that ABVD alone
was equivalent to MOPP/ABV hybrid, but with reduced
acute haematological toxicity and secondary AML/MDS.
ABVD is therefore considered equivalent or possibly more
eﬃcacious than MOPP, but signiﬁcantly less toxic [19].
5.1. Increasing Eﬃcacy with Higher Intensity Regimens. Sev-
eral groups have tried to develop more intensive chemother-
apy regimes, by either escalating doses and number of drugs
or reducing the dosing interval.
5.1.1. BEACOPP-Based Regimens(Bleomycin,Etoposide, Dox-
orubicin (Adriamycin), Vincristine (Oncovin), Procarbazine,
and Prednisolone). The GHSG developed the BEACOPP
regimen based on mathematical modelling to increase dose
density and intensity [20]. Three variants have been trialled:
standard BEACOPP (SB), escalated BEACOPP (EB), and
BEACOPP-14, which is accelerated over a 14-day cycle.
In the EB regimen doses of cyclophosphamide, etoposide,4 Advances in Hematology
Table 3: Trials of treatments for early stage favourable Hodgkin’s lymphoma. Numbers in bold are statistically signiﬁcant with P values
where signiﬁcant. Abbreviations: OS: overall survival; EF RT: extended-ﬁeld radiotherapy; IF-RT: involved-ﬁeld radiotherapy; STLI:
subtotal lymphoid irradiation; Gy: gray; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; AV: doxorubicin, vinblastine; EBVP:
epirubicin, bleomycin,vinblastine, and prednisolone; MOPP/ABV:mechlorethamine, vincristine, procarbazine, prednisolone, doxorubicin,
bleomycin,andvinblastine;SWOG:SouthwestOncologyGroup; GELA: Group d’Etudes des Lymphomesle l’Adulte; NCIC: NationalCancer
Institute of Canada; ECOG: Eastern Co-operative Oncology Group; MSKCC: Memorial Sloan Kettering Cancer Center.
Treatment regimen
(author/trial) No. of Pts Outcome
( % ,m e a s u r e ,t i m e ) OS (%) Haem toxicity
(% Gr III-IV)
All acute toxicity
(% grade III-IV)
Second malignancy
(haem/solid,%)
STLI (36–40Gy) 161 81 (FFS 3y) >95% 42 — —
3AV + STLI (36–40Gy) 165 94 >95% 57 ——
(Press SWOG2001) P<. 001 P = .004
EF RT 30Gy (+10Gy IF RT) 311 67 (FFTF 7y) 92 0.8 — 3.2
2ABVD + EF RT 30Gy (+10Gy
IF RT) 316 88 94 14.8 — 2.2
(Engert GHSG-HD7 2007) P<. 001
STLI 165 78 (EFS 10y) 92 — — 1/2
6EBVP + IF RT (36–40Gy) 168 88 92 — — 1/0.01
(Noordijk EORTC-H7F 2006) P = .0113
STLI 272 74 (EFS 5y) 92 (10y) — — 0/2
3MOPP/ABV + IF RT (36Gy) 270 98 97 —— 0 / 2
(Ferme EORTC/GELA-H8F
2007) P<. 001 P<. 001
4ABVD + STLI RT 136 93 (12y FFP) 96 — — 1.5/3
4ABVD + IF RT 94 94 — — —
(Bonadonna Milan 2004)
4ABVD + IF RT 1370 93 (FFTF 5y) 97 24 52
2ABVD + IF RT 91 97 15 33
ABVD + IF RT (30Gy) 93 98 8.7
ABVD + IF RT (20Gy) 93 93 2.9
(Engert GHSG-HD10 2009)
STLI 64 88 (5y FFP) 100 — — —
4–6ABVD 59 87 97 — — —
(Meyer NCIC/ECOG HD6 2005)
6ABVD + IF/EF RT 76 86 (5y FFP) 97
6ABVD 76 81 90
(Straus MSKCC 2004)
and doxorubicin are increased by 192%, 200%, and 140%,
respectively. The seminal trial of SB and EB was the GHSG
HD9 study [21]. 1196 patients were randomised between a
baseline arm of 8 cycles of alternating COPP (cyclophos-
phamide replacing mechlorethamine in the MOPP regi-
men)/ABVD and SB or EB. 10-year FFTF and OS showed
an advantage for treatment with EB [22]. Acute toxicity was
higherwith signiﬁcantly more haematological and infectious
toxicity, but no diﬀerence in nonrelapse mortality (NRM)
of 7%. Secondary leukaemias/MDS were increased in both
BEACOPP regimens, and infertility was universal.
This important trial provided for the ﬁrst time a more
eﬀective, but toxic, regimen that could be used to improve
theoutcomesforthoseathighestrisk ofrelapse. Interestingly
EB beneﬁted all IPS groups implying that this would not be
a good method of identifying those most likely to beneﬁt.
The use of EB has not become widespread, however, as
a number of criticisms can be made of the study. The
control arm would not be considered to be the standard
of care in most centres and the outcomes for ABVD alone
have improved compared to historical comparisons. In
addition, COPP/ABVD was given over a median of 46.3
days compared to a planned period of 30 days. AVBD, in
contrast, is routinely delivered on time. In the HD9 study
the more intensive SB and EB regimens were given, on
time, over a median of 24.3 and 24.7 days, respectively.
A largeconﬁrmatory multicentreRCTcomparingSB/EBand
modern, on-time ABVD alone is eagerly awaited by many
who are concerned that the acute toxicity, infertility, and late
malignancy associated with BEACOPP outweigh the beneﬁts
of early disease control.
Despite promising results, some patients continue to
relapse. Patients with the highest IPS scores (4–7) treated
with EB fare better than with COPP/ABVD, but still haveAdvances in Hematology 5
Table 4: Trials of treatments for early stage unfavourable Hodgkin’s lymphoma. Numbers in bold are statistically signiﬁcant with P values
where signiﬁcant. ∗Treatment discontinuation due to haematological intolerance. Abbreviations: OS: overall survival; EF RT: extended-
ﬁeld radiotherapy; IF-RT: involved-ﬁeld radiotherapy; STLI: subtotal lymphoid irradiation; Gy: gray; ABVD: doxorubicin, bleomycin,
vinblastine, and dacarbazine; EBVP: epirubicin, bleomycin, vinblastine, and prednisolone; MOPP/ABV: mechlorethamine, vincristine,
procarbazine, prednisolone, doxorubicin, bleomycin, and vinblastine; COPP/ABVD: cyclophosphamide, vincristine, procarbazine, and
prednisolone/ABVD; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone.
Treatment regimen
(author/trial)
No. of
Pts
Outcome
( % ,m e a s u r e ,t i m e ) OS (%) Haem toxicity
(% grade III-IV)
Second malignancy
(haem/solid,%)
3 MOPP + Mantle RT + 3 MOPP 165 77 (FFP 6y) 85 14.5 —
3 ABVD + Mantle + 3 ABVD 151 88 91 7.3∗ —
(Carde EORTC H6U 1993) P = .01
6EBVP + IF RT (36Gy) 194 68 (EFS 10y) 79 — 4/5
6 MOPP/ABV + IF RT 195 88 87 —2 / 2
(Noordijk EORTC H7U 2006) P<. 001 P = .0175
2ABVD + STLI 139 95 (FFP 5y) 92 — —
4–6ABVD 137 88 95 — —
(Meyer NCI-C/ECOG HD6 2005) P = .004
6 MOPP/ABV + IF RT (36Gy) 336 82 (EFS 10y) 88 — 2/2
4 MOPP/ABV + IF RT (36Gy) 333 80 85 — 3/3
4 MOPP/ABV + STLI 327 80 84 — 2/2
(Ferme EORTC-GELA H8U 2000)
4 COPP/ABVD + EF RT (30Gy) +
Bulky 10Gy 532 86 (FFTF 5y) 91 5.8 2.2/2.3
4 COPP/ABVD + IF RT (30Gy) +
Bulky 10Gy 532 84 92 2.5 1.2/1.7
(Engert GHSG HD8 2003) P<. 001
Table 5: Trials comparing MOPP- and ABVD-based regimens for the treatment of advanced stage Hodgkin disease. Numbers in bold are
statistically signiﬁcant with P values where signiﬁcant. ∗Febrile neutropenia. Abbreviations: OS: overall survival; MOPP: mechlorethamine,
vincristine, procarbazine, prednisolone; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; MOPP/ABV: mechlorethamine,
vincristine, procarbazine, prednisolone, doxorubicin, bleomycin, and vinblastine.
Treatment regimen
(author/trial) No. of Pts Outcome
( % ,m e a s u r e ,t i m e ) OS (%) Haem toxicity
(% grade III-IV)
Second malignancy
(haem/total, %)
MOPP 198 54 (FFP 20y) 48 — <2/− (10y)
(Longo 1986)
MOPP 43 36 (FFP 8y) 64 — —
MOPP/ABVD alternating 45 65 84 ——
(Bonadonna 1986) P<. 005 P<. 06
6–8 MOPP 123 50 (FFS 5y) 66 Increased —
MOPP/ABVD alternating ×12 123 61 73 — —
6–8 ABVD 115 65 75 — —
(Canellos 1992)
MOPP/ABVD alternating 211 67 (FFP 10y) 74 — —
MOPP/ABVD hybrid 204 69 72 — —
(Viviani 1996)
MOPP/ABV hybrid 153 71 (FFS 5y) 81 18∗ —
MOPP/ABVD alternating 148 67 83 7 —
(Connors 1997) P = .0001
MOPP/ABV 419 66 (FFS 5y) 81 75 3/7
ABVD 433 63 82 64 0.005/4
(Duggan 2003) P = .001 P = .0116 Advances in Hematology
a30%10-yearmortality. Anothergroupwith apoorprogno-
sis thatdoesnotrespond todose escalation isthe elderly.The
GHSGHD9elderly studyrandomised26patientstoalternating
COPP/ABVD and 42 patients to SB [23]. EB was deemed too
toxic to study, and the COPP/ABVD arm was shut early due
to the results of HD9. Despite the COPP/ABVD arm having
more unfavourable patients, no beneﬁt to 5-year FFS (46%)
or OS (50%) was demonstrated. Toxicity in the SB arm was
high; only 38% of patients received the intended dose, TRM
was 21% compared to 8% in the COPP/ABVD arm, and the
incidence of any grade III-IV toxicity was 87% compared to
44% in COPP/ABVD.
The only other randomised comparison of a BEACOPP
regimen comes from the Italian GISL HD 2000 trial [24]. In
this study 4 cycles of BEACOPP (2EB, 2SB) were com-
paredtoanotherintensiveregimenCEC(cyclophosphamide,
lomustine, vindesine, melphalan, prednisolone, epidoxoru-
bicin, vincristine, procarbazine, vinblastine, and bleomycin
COPPEBVCAD) and a control group treated with ABVD.
Only 81 patients were randomised to BEACOPP, but it
did show a signiﬁcantly better 5-year FFS. There was no
diﬀerence in CR or OS, partly due to salvage treatments.
BEACOPP had more grade III-IV haematological and infec-
tioustoxicity,butit was less toxicthan reported in the GHSG
HD9 study.
5.1.2. Strategies to Reduce BEACOPP Toxicity. An u m b e ro f
groups are investigating strategies to capitalise on the eﬀec-
tiveness of EB, whilst minimising toxicity. Most strategies at
present are attempting to minimise the number of EB cycles,
either by protocol or interim PET assessment of response.
The GHSG HD12 trial employs a 2-by-2 design testing
8 × EB or 4 × EB/4 × SB followed by consolidation RT or
observation [25]. Interim results of 1571 patients showed
no diﬀerence in 5-year PFS or OS. Other GHSG studies
investigating BEACOPP include the HD15 (8 × EB versus
8 × SB versus 6 × SB with a completion PET to decide
on consolidation RT) and HD18 (2 × EB then escalate or
de-escalate based on a PET scan, see later). The concept of
mixing EB and SB is supported by an interim report of 321
patients treated by the Italian Intergroup showing better 3-
year FFP in 4 × EB-4SB compared to 6–8 cycles of ABVD
(87% versus 71%, P = .01) [26].
A second strategy under evaluation by the GHSG is to
time-intensify BEACOPP into 14 days reducing the cumula-
tive doses of agents that cause acute toxicity and secondary
malignancy. Phase II dataon94 patients treated with 8 cycles
of BEACOPP-14 by the GHSG showed 3-year rates of CR,
FFTF, and OS of 94%, 97%, and 90%, respectively. 75% of
cases experienced grade III-IV leukopenia resulting in a 12%
rate of serious infection [27].
5.1.3. Other Intensive Regimens. The Stanford group devel-
oped a 12-week regimen to time intensify certain agents and
de-escalate/omit more toxic agents (Stanford V: doxoru-
bicin, vinblastine, mechlorethamine, vincristine, bleomycin,
etoposide, and prednisolone). Integral to this regimen was
radiotherapy to any bulky disease (>5cm), macroscopic
splenic disease, or persistent disease by CT criteria after
treatment. Pilot studies showed encouraging results with
5-yearFFPandOSof85–89%and96%,respectively[28,29].
An Italian Intergroup trial of 355 patients randomised to
Modiﬁed Stanford V, MOPPEBVCAD, or ABVD showed
disappointing results for modiﬁed Stanford V, but the aim
of the study was to minimise radiotherapy exposure which
undermined the strategy ofthe Stanford protocol[30]. A UK
NCRIstudyof520patientsrandomisedtoABVDorStanford
Vw i t ha sp r o t o c o lR Ts h o w e dn od i ﬀerence in FFS/OS [31].
Another UK study, the LY09 trial, also failed to show
any beneﬁt of a multidrug regimen (ChlVPP/PABIOE versus
ChlVPP/EVA ±RTX, see Table 6 fordetails)overABVD[32].
5.2. Consolidation Treatment
5.2.1. Consolidation Radiotherapy. Patients with poor risk
features such as bulky disease or residual lesions by CT or
PET criteria might be potential candidates for consolidation
radiotherapy. This approach has the advantage of being
less toxic than ASCT. The EORTC investigated 739 patients
treated with MOPP/ABV chemotherapy [33]. If patients
achieved CR (n = 512), they were randomised to IF RT or
observation. Those achieving PR (n = 227) received RT. 8-
year EFS and OS were the similar in each group suggesting
a beneﬁt for IF RT in the PR group. No diﬀerence in the
rate of second malignancies was noted. The GELA H89
trial randomised patients to chemotherapy with either 6 ×
MOPP/ABV or ABVPP [34]. Those achieving CR or PR
received consolidationwith 2 further cyclesofchemotherapy
(n = 208) or STLI (n = 210). RT was not superior to
chemotherapy consolidation. The GHSG HD15-PET study
investigated patients treated with BEACOPP with residual
disease >2.5cm [35]. These cases proceeded to have a PET
and were given RT on panel decision. PET-positive cases
had a 1-year PFS of 96% compared to 86% if PET negative
(P = .011). End of treatment PET positivity predicted
for relapse within one year, despite additional radiotherapy.
The above trials and a systematic review by Loeﬄer have
contributed to abandon consolidation RT for patients in CR
after chemotherapy [36].
A systematic review of the sensitivity and speciﬁcity of
interim PET in advanced lymphoma identiﬁed 360 cases
of advanced CHL in 13 studies [37]. Interim PET showed
asensitivityof0.81(95%CI0.72–0.89)andspeciﬁcityof0.97
(95% CI 0.94–0.99) indicating that an approach of targeted
IF RT based on PET is a reasonable consolidation strategy in
selected patients failing to achieve CR.
5.2.2. Autologous Stem Cell Transplant. Consolidation high-
dose therapy and ASCT of patients at very high risk of
relapsehasbeeninvestigatedbysomegroupsinsmallstudies.
The Scotland and Newcastle Lymphoma Group HD3 trial
identiﬁed 65 “highest-risk” patients based on age, stage,
lymphocyte count, baseline haemoglobin, and presence of
bulky disease [38]. Patients were given 3 cycles of PVACE-
BOP chemotherapy and then randomised to either ASCT
or 2 further cycles of chemotherapy. No diﬀerences in 6-
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or OS were found. The European Intergroup identiﬁed
“unfavourable” cases based on 2 of high LDH, large medi-
astinal mass, >1extranodal site, low haematocrit, or inguinal
involvement [39]. Those achieving PR/CR after 4 cycles of
ABVD were randomized to 4 more cycles of ABVD (n = 80)
or ASCT (n = 83). 5-year FFS and OS were not signiﬁcantly
diﬀerent. Consensus opinion is therefore that ASCT in ﬁrst
CR is not indicated.
6.LateEffects
With the advent of chemotherapy regimens that can increase
diseasecontrolattheexpenseoflateeﬀects,riskstratiﬁcation
is rapidly being incorporated into standard practice. When
considering the risks of late eﬀects it is important to distin-
guish between relative (RR) and absolute (AR) risk and in
particular how this aﬀects long-term survival.
6.1. Second Malignancy. Solid malignancies account for the
majority(59–80%)ofsecondmalignancies. Youngerpatients
haveahigher RRduetotheir low baseline risk, whereas older
patients have a higher AR particularly for carcinoma of the
lung. Risk is related to exposure to both chemotherapy and
RT, but the risk from chemotherapy seems to plateau.
The RR of haematological malignancies, in particular
acute myeloid leukaemia (AML) and myelodysplastic syn-
drome (MDS), is signiﬁcantly raised during the ﬁrst decade
of followup. ABVD appears to confer a relatively small risk
of AML/MDS compared to MOPP- or BEACOPP-based
regimens [19, 22, 30].
6.2. Fertility. ABVD chemotherapy appears to have relatively
mild eﬀects on fertility. A small study of 36 women treated
with 4–6 cycles of ABVD showed that 70% could conceive
within 1 year compared to 75% of controls [40]. Data from
the EORTC H6-9 study of 355 males with early stage HD
looked at elevation of follicle stimulating hormone (FSH)
as a marker of gonadal damage [41]. FSH was elevated
in 3% after RT, 8% of men treated with chemotherapy
containing no alkylating agents and 60% of men treated
with regimens such as MOPP or BEACOPP that contain
alkylators. At 19 months FSH returned to baseline in 82%
of those not exposed to alkylating agents, compared with
only 30% treated with alkylating agents. The GHSG has also
demonstrated 100% azoospermia or dyspermia in 38 males
treated with 8 cycles of SB or EB, although interestingly only
23%were normozoospermic priortostarting chemotherapy.
Median time to recovery was 3.6 years [42]. A small GHSG
study of ovarian protection in 23 women treated with EB
using either the oral contraceptive or a GnRH analogue
showed no beneﬁt of either intervention [43]. 12-month
levels of antimullerian hormone (AMH) were reduced in all
with a0%ovarian folliclepreservationrate(95%CI0–12%).
6.3. Cardiovascular. Data on late eﬀects on the cardiovas-
cular system are less complete, but a range of adverse
outcomes have been reported including coronary artery
disease (CAD), left ventricular dysfunction (LVD), valvular
stenoses, pericardial disorders, and other vascular diseases
such as carotid or subclavian artery stenoses. Relative risks
of dying from CAD are increased by 5 with an absolute risk
of 10–12% at 15–25 years. This risk is disproportionately
increasedbythepresenceofconventionalcardiacriskfactors,
which should be optimised. RR of symptomatic valvular
disease requiring valve replacement is 8-9 times higher with
an absolute risk of 6% at 20 years.
6.4. Pulmonary. Rates of bleomycin lung toxicity have been
reported to be as high as 30% in the US intergroup study
and were related to age and prior RT [18]. Rates of fatalities
are approximately 1.5–2% [18, 31]. Some are questioning
the value of bleomycin in the ABVD regimen, and this
was supported by a retrospective review showing reasonable
outcomes in 40 patients discontinuing bleomycin due to
dyspnoea [44].
7.RiskAdaptedTreatment
Various strategieshavebeenemployedbycooperativegroups
to stratify patients into risk groups at presentation so as
to target initial treatment intensity. Clinical scores such as
the IPS are in widespread use, but interestingly the beneﬁt
of EB was spread across all IPS risk groups. A number
of biomarkers have been evaluated including morphology,
immunophenotype (e.g., CD15, CD20), apoptotic proteins
(e.g., Bcl-2), T-cell composition, measuring tumour burden
(e.g., B2MG, soluble CD30), or in situ EBV. None of these is
currently in widespread clinical use.
7.1. Assessing Chemosensitivity by Interim PET. Initial
response to chemotherapy has been investigated as a prog-
nostic marker. A large Italian/Danish observational study of
260 patients studied the prognostic value of a PET after 2
cycles (PET2) of chemotherapy [45]. Cases that were PET
positive after 2 cycles (19%) had a 2-year FFS of 12.8%
compared to 95% in the PET negative group. PET2 was
predictive of outcome across IPS scores, and, in a multi-
variate analysis PET2, stage IV and age over 45 were the most
signiﬁcant prognostic markers. Concerns have been raised,
however, about the uniformity of PET reporting.
Dann et al. [46] published a small, nonrandomised study
of risk-adapted therapy based on PET2 results. 108 patients
were given 2 cycles of SB (IPS 1-2) or EB (IPS 3–7) and then
underwent PET assessment. PET-positive patients received
4 cycles of EB and PET negative 4 cycles of SB. 69 cases
started with SB of which 14% (n = 10) were escalated to
EB after PET2. 39 cases started with EB, and 79% (n = 31)
were de-escalated to SB. Only 7 cases received 6 cycles of EB.
There were no diﬀerences in 5-year PFS (85%) or OS (90%)
between the groups. Interestingly, PET2 had a high negative
predictivevalue(98%)forprogression,butasurprisinglylow
positive predictive value (27%), suggesting a beneﬁcial eﬀect
of intensive treatment in the higher-risk patients. Another
observation in this study was that 9 of 10 cases that were
escalated had residual PET positivity at the end of treatment
(including radiotherapy consolidation). In 7 of 9 cases this
regressed over 14 months, and these patients remain in CR.8 Advances in Hematology
Table 6: Trials of treatments currently under investigation for the treatment of advanced stage Hodgkin disease. Numbers in
bold are statistically signiﬁcant with P values where signiﬁcant. Abbreviations: OS: overall survival; RT: radiotherapy; MOPP:
mechlorethamine,vincristine,procarbazine,andprednisolone;ABVD:doxorubicin,bleomycin,vinblastine,anddacarbazine;COPP/ABVD:
cyclophosphamide, vincristine, procarbazine, and prednisolone/ABV D ;B E A C O P P :b l e o m y c i n ,e t o p o s i d e ,d o x o r u b i c i n ,c y c l o p h o s p h a m i d e ,
vincristine, procarbazine, and prednisolone; CEC: cyclophosphamide, lomustine, vindesine, melphalan, prednisolone, epidoxorubicin,
vincristine, procarbazine, vinblastine, and bleomycin; Stanford V: doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin,
etoposide, and prednisolone; MOPPEBVCAD: mechlorethamine, vincristine, procarbazine, prednisolone, epidoxorubicin, bleomycin,
vinblastine, lomustine,doxorubicin, and vindesine; MDR ChIVPP:(chlorambucil, vinblastine, procarbazine, and prednisolone) alternating
either with PABIOE (prednisolone, doxorubicin, bleomycin, vincristine, and etoposide) or EVA (etoposide, vincristine, and doxorubicin);
ASCT: autologous stem cell transplant.
Regimen
(author, trial)
No. of
Pts CR (%) Outcome
( % ,m e a s u r e ,t i m e ) OS (%) RT (%)
Haem
toxicity/infections
(gr III-IV, %)
Second
malignancy
(haem/total, %)
6–8 MOPP 123 67 50 (FFS 5y) 66
MOPP/ABVD alternating ×12 123 83 61 73
6–8 ABVD 115 82 65 75
(Canellos 1992)
8COPP/ABVD 261 85 64 (FFTF10y) 75 64 71/3 0.4/5.3
8BEACOPP 469 88 70 80 71 73/16 2.2/7.9
8EscBEACOPP 466 96 82 86 71 98/22 3.2/6.5
(GHSG HD9 2003) P<. 0001 P = .005 P = .03
6ABVD 99 70 65 (FFS 5y) 84 46 34/2 0/1
BEACOPP 4 escalated, 2 baseline 98 81 78 92 44 54/14 0/1
6CEC 98 69 71 91 43 48/4 1/2
(Federico—GISL HD2000— 09) P = .036 versus
ABVD P = .016/P = .003
8 × BEACOPP-14 ± RT 94 94 97 (FFTF 3y) 90 70 75/12 1/1
(Sieber GHSG Phase II 2003)
6ABVD 122 89 78 (FFS 5y) 90 76 25/1 0/0
3Mod Stanford V 107 76 54 82 71 29/0 1/2
6MOPPEBVCAD 106 94 81 89 50 51/14 4/4
(Gobbi Italian Intergroup 2005) P<. 01
ABVD 261 46 76 (PFS 5y) 90 53 — 0.004/0.02
Stanford V 259 44 74 92 73 — 0.012/0.02
(Hoskin UK NCRI 2009)
ABVD ± RT 406 68 75 (3y) 90 37 56 0/−
MDR ± RT 401 67 75 88 49 65 −/−
(JohnsonUK LY09 2005)
8ABVD 80 89 82 (FFS 5y) 88 — — —
4ABVD + ASCT 83 92 75 88 — — —
(Federico EBMT HD01 2003)
Ongoing phase III studies of interim PET scanning
include the UK RATHL and GHSG HD18 studies. RATHL
treats patients with 2 cycles of ABVD and then has a double
randomisation: if PET2-positive patients are escalated to
either BECOPP-14 or EB, if PET2-negative patients receive
either ABVD or AVD. HD18 starts patients with 2EBs and
then randomises PET2+ patients to 6EB with or without
rituximab and PET2-negative patients to 2 or 6 cycles of EB.
7.1.1. Current Standard of Care and Future Directions. The
currentstandard of carein advanced Hodgkin’s lymphoma is
contentious. Most clinicians continue to support 6–8 cycles
of ABVD as standard. EB is an option in patients at higher
risk, but many await a conﬁrmatory phase III trial. PET
positivity after 2 cycles of chemotherapy is emerging as
a powerful predictive tool, and studies are investigating if
escalation or de-escalation of therapy after PET2 beneﬁts
high- or low-risk cases, respectively. Using end-of-treatment
PET scanning todirect consolidation RTmay be beneﬁcialto
those not achieving CR.
Even in advanced stage disease, however, the majority
of patients will achieve long-term disease control. Eﬀorts to
improve OS by limiting toxicity include limiting number of
cycles of chemotherapy, removing more toxic drugs such asAdvances in Hematology 9
bleomycin or doxorubicin, and incorporating new, less toxic
agents into current regimens. Trials in this area will have to
report progressively longer followups if true reductions in
late toxicity are to be proven.
8.Relapsed/Refractory
Approximately 5–10% of cases will suﬀer primary refractory
disease deﬁned as no response or progression within 90 days
of treatment, and a further 10–30% will relapse [47]. These
patients have a poor prognosis if treated with conventional
chemotherapy alone. In a single-centre historical review of
107 patients Longo et al. [48] demonstrated a CR rate of
49%, but this was durable in only 5–10%, and median
survival was 16 months. Those relapsing after one year (late
relapses) had a signiﬁcantly improved CR and OS rate (80%
and 25%) compared to those with early relapses (50% and
10%) despite high rates of secondary AML in the survivors.
Another review of 115 relapsed or refractory patients treated
with MOPP/ABVD + RT showed 8-year rates of FFSP and
OS to be 22% and 28% in early relapses and 44% and 54%,
late relapse [49]. Those with primary progressive disease had
the worst prognosis (FFSP 0% and OS 8%).
9.High-Dose ChemotherapyandASCT
2 randomised controlled trials have established the beneﬁt
of high-dose chemotherapy and ASCT in relapsed and
refractory CHL. A UK BNLI study randomising 40 patients
to mini-BEAM or BEAM ASCT showed 3-year EFS of 10%
versus 53% in the ASCT arm (P = .025) [50]. No diﬀerence
inOSwasfoundattheearly followup.AlargerEMBT/GHSG
randomised 161 chemosensitive patients having received 2
cycles of salvage dexa-BEAM to either 2 further cycles or
BEAM ASCT [51]. 3-year FFTF was better in the ASCT arm
(55% versus 34%, P = .019) with no diﬀerence in OS,
although a large number of deaths were noted during all
cycles of dexa-BEAM.
Whether ASCT beneﬁts chemorefractory cases remains
unclear. Registry data such as the Seattle series of 64 patients
have shown encouraging results (5-year PFS 17% and OS
31%), but current practice is to maximise overall response
during salvage chemotherapy [52].
9.1. Tandem ASCT. Some groups have advocated the use of
tandem ASCT in very high-risk cases. In 43 patients with
inductionfailure orvery-unfavourablerelapse 2-yearOSwas
65% (0% if no ASCT, 40% if 1 ASCT, and 74% if tandem
ASCT) [53]. The nonrandomised GELA H96 trial treated
150 high-risk patients (primary refractory or 2 of relapse
within 1 year, relapse in radiation ﬁeld, and stage III/IV at
relapse) with tandem ASCT compared with 95 cases with
intermediate risk relapse (one of the above risk factors)
who underwent single ASCT [54]. Fewer than 70% of high-
risk patients tolerated both transplants, but outcomes were
promising with 5-year freedom from second failure (FF2F)
of 73% and 46% and OS of 85% and 57% in intermediate-
and high-risk arms, respectively.
A high-dose sequential approach (2 cycles of DHAP, cy-
clophosphamide + GCSF and stem cell collection followed
by methotrexate and vincristine, etoposide, and BEAM con-
ditioned ASCTversusconventionalASCTis underinvestiga-
tion by the GHSG [55].
10.SalvageChemotherapyRegimens
With the evidence indicating improved outcomes in chemo-
sensitive patients undergoingASCT,the overallresponse rate
(ORR) of salvage chemotherapy and ability to subsequently
harvest stem cells are critical. No randomised trials have
compared salvage regimens; results of phase II studies are
compared in Table 7, and overlapping conﬁdence intervals
suggest no major diﬀerences in ORR [56–66]. Pending more
information on eﬃcacy, the choice of salvage chemotherapy
is therefore based on expected tolerability and the treating
centre’s experience.
11.SalvageRadiotherapy
Salvage treatment with radiotherapy may be appropriate in
selected cases. The GHSGretrospective analysed 100patients
treated with RT alone at disease progression. 5-year FFTF
was 29% and OS 51% with an ORR of 81%. This was worse
in advanced stage, early relapse, or poor performance score
patients [67].
12.AllogeneicStemCell Transplantation
12.1. Myeloablative Allografting. Treatment-related mortal-
ity (TRM) of multiple relapsed CHL patients treated with
myeloablative allogeneic stem cell transplant (AlloSCT) is
prohibitive at 48%–61% (Table 8)[ 68–72]. Even in patients
treatedearlierintheirdiseaseattheJohnsHopkinsOncology
Center, total TRM was 42% with a 10-year PFS of only
26% [71]. An EBMT study matched 45 cases of AlloSCT to
ASCTdemonstrating aTRM of48%versus27% (P = .0411)
that rose to 65 versus 12% (P = .0054) in chemosensitive
patients. Myeloablative AlloSCT is therefore not recom-
mended in relapsed CHL [69].
12.2. Reduced Intensity Conditioned (RIC) Allografting. RIC
AlloSCTs oﬀer a strategy to reduce TRM but require graft
versuslymphoma(GvL)activityfordiseasecontrol.Evidence
for GvL activity can come from increased relapse rates after
T-cell depletion, the association of graft-versus-host disease
(GvHD) with reduced relapse rates, and most convincingly
responses to donor leukocyte infusions [73].
Published outcomes of RIC strategies in CHL are sum-
marised in Table 9 [74–78]. An EBMT study comparing 89
RIC to 79 myeloablative AlloSCTs showed an improved 3-
year TRM of 24% versus 48% (P = .003) and signiﬁcantly
better 5-year OS [78]. An association of chronic GvHD
to reduced risk of relapse was noted, but conditioning
intensity was also important with total body irradiation
being associated with adverse outcome. It is important that
steroid treatment of GvHD does not confound the reporting10 Advances in Hematology
Table 7: Summary of outcomes of nonrandomised trials of salvage treatments in relapsed and refractory Hodgkin’s lymphoma, arranged
in descending order of ORR. Abbreviations: CR: complete remission; PR: partial remission; ORR: overall response rate; TRM: treatment-
related mortality;DHAP: dexamethasone,cytarabine, and cisplatin;ICE: ifosfamide,carboplatin,andetoposide; IVE: ifosfamide,etoposide,
and epirubicin; IV: ifosfamide, vinorelbine; Mini-BEAM: BCNU, etoposide, cytarabine, and melphalan; Dexa-BEAM: dexamethasone,
carmustine, etoposide, cytarabine, and melphalan; ESHAP: etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; ASHAP:
doxorubicin, methylprednisolone, high-dose cytarabine, and cisplatin; MINE: mitoguazone, ifosfamide, vinorelbine, and etoposide; GVD:
gemcitabine, vinorelbine, and pegylated liposomal doxorubicin; GDP: gemcitabine, dexamethasone, and cisplatin.
Regimen No. of CR % PR % ORR % Neutropenia Thrombocytopenia Vomiting TRM %
Pts (95% CI) (95% CI) (95% CI) % Gr 3/4 % Gr 3-4 % Gr 3-4 (95% CI)
DHAP [54] 102 21 68 89 88 69 26 0
13–29 59–77 83–95 0–4
ICE [55] 65 26 59 88 — — — 0
16–39 46–71 74–92 0–5
IVE [56] 51 61 22 84 100 — — 0
71–93
Mini-BEAM [57] 55 51 33 84 86 60 — 2
35–63 21–47 69–91 0.1–10
IV [58, 59] 47 45 38 83 65 0 2 —
30–60 25–54 69–92
MINE [60] 157 — — 75 — — — 5
64–84
ASHAP [61] 56 34 36 70 100 — — 0
GVD [62] 91 19 51 70 68 28 1 1
60–80
GDP [63] 23 17 52 69 9 13 13 0
5–39 31–73 52–87 0–15
Dexa-BEAM [64] 55 31 29 60 >90 >90 — 5
46–73 1–9
Table 8: Registry data of outcomes of myeloablative allogeneic transplants in relapsed and refractory Hodgkin’s lymphoma. Abbreviations:
Sib/UD: Sibling/unrelated donor; PFS: progression-free survival; OS: overall survival; TRM: treatment-related mortality; IBMTR:
International bone marrow transplant registry; EBMT: European Group for Blood and Marrow Transplantation;FHCRC: Fred Hutchinson
Cancer Research Center; JHOC: Johns Hopkins Oncology Center.
Study
(group, author) No. of pts Sib/UD Median age
(range)
PFS
(%, years) OS (%) TRM (%)
IBMTR 100 100 28 15 (3y) 21 61
(Gajewski 1996) (12–44)
EBMT 45 45 29 15 (4y) 25 48
(Milpied 1996) (15–42)
FHCRC 53 50/3 29 18 (5y) 21 49
(Anderson 1993) (10–55)
JHOC 53 53 28 26 (10y) 30 43 (total)
(Akpek 2001) (13–52)
EBMT 167 145/12 24 16 (4y) 25 52
(Peniket 2003) (7–57)
of disease responses to DLI. Studies by Alvarez et al. [76],
Peggs et al. [75], and Anderlini et al. [79]h a v es h o w na n
association between DLI and the development of GvHD
with durable disease responses in approximately 50% of
cases. Interestingly T-cell depletion with alemtuzumab has
been shown to reduce chronic GVHD, without increasing
relapse rate leading some to suggest that this may be due
to a reduction in T-regulator cell inhibition of antitumour
cytotoxic T cells [80].
A UK study compared 38 RIC AlloSCTswith 34 matched
historical controls that had responded to salvage treatment
and survived for one year and hence were deemed ﬁt enoughAdvances in Hematology 11
Table 9: Registry data of outcomes of reduced intensity conditioned (RIC) allogeneic transplants in relapsed and refractory Hodgkin’s
lymphoma. Numbers in bold are statistically signiﬁcant with P values where signiﬁcant. ∗Antithymocyte globulin given to unrelated donor
recipients. Abbreviations: Sib/UD: sibling/unrelated donor; PFS: progression-free survival; OS: overall survival; TRM: treatment-related
mortality; M: melphalan; F: ﬂudarabine; A: alemtuzumab; MDACC: MD Anderson Cancer Center; EBMT: European Group for Blood and
Marrow Transplantation.
Study
(group, author) No. of pts Sib/UD Median age
(range)
PFS
(%, years) OS (%) TRM (%)
RIC 52 −/− 30 42 (2y) 56 17
(EBMT Robinson 2002) 15–53
MF-A 49 31/18 32 39 (4y) 56 16 (2y)
(UK Peggs 2005) 18–51
MF∗ 40 38/2 31 32 (2y) 48 25 (1y)
(Spain Alvarez 2006) 16–53
MF∗ 58 25/33 32 32 (2y) 64 15
(MDACC Anderlini 2008) 19–59
Myeloablative 79 70/9 27 (11–60) 20 (5y) 22 48 (3y)
RIC 89 77/12 26 (5–61) 18 28 24
(EBMT Sureda 2008) (.04) P = .003
to undergo RIC [81]. 5-year current PFS and 10-year OS
from diagnosis were 42% and 48% in the RIC armcompared
to 18% (P = .075) and 15% (P<. 0001) in the control
group. 5-year NRM was a more favourable 19%, and DLI
responses were seen in 8 of 15 patients.
12.3. Current Standard of Care and Future Directions. High-
dosetherapy andautologousstemcellrescue isestablished as
thetreatment ofchoicein relapsed and refractory CHL.Out-
comes are signiﬁcantly better if patients have chemosensitive
disease prior to transplant [82]. A number of salvage regi-
mens exist, but they have not been compared in randomised
controlled trials; overlapping conﬁdence intervals suggest no
major diﬀerences in eﬀectiveness.
Allogeneic transplantation as a therapeutic option for
patients with second relapse or refractory disease who
respond tochemotherapy isan exciting therapeuticmanoeu-
vre that continues to be studied. Although myeloablative
protocols are associated with prohibitive toxicity, RIC trans-
plantationoﬀerslower TRM and the possibility ofprolonged
DFS in multiple relapsed patients, particularly using DLI.
Randomised trials are needed to deﬁne which patients
would beneﬁt most, to identify optimal conditioning, and to
evaluatetheimportanceofresponsetosalvagechemotherapy
on outcome.
13.ExperimentalTherapies
Due to the success of conventional treatments in managing
H L ,t h en u m b e ro fp a t i e n t sa v a i l a b l et ot r i a ln o v e la g e n t si s
limited. Clinical circumstances that particularly merit their
investigation include multiple relapse/refractory patients,
those PET+ after salvage therapy and the elderly.
13.1. Monoclonal Antibodies. Following the success of ritux-
imab in CD20 positive non-Hodgkin lymphoma, a number
of diﬀerentially expressed CHL cell surface markers have
been evaluated as targets for monoclonal antibody (mAb)
therapy (Table 10).
13.1.1. CD30. CD30 is densely expressed and highly
restricted on CHL cells, existing as a membrane-bound
and a soluble form. Early trials of anti-CD30 mAbs were
disappointing due to poor binding, poor activation of
immune response, and quenching by soluble CD30 [83, 84].
Strategies to improve antibody performance have included
designing mAbs to be selective for the membrane form and
humanising the antibody. One promising strategy is by-
passing antibody-mediated cellular cytotoxicity to conjugate
the mAb to an antimicrotubule agent (SGN-35). Early trials
of SGN-35 have shown promising ORRs of between 39 and
47% with updated results expected imminently [85, 86].
The AETHERA trial is investigating SGN-35 maintenance
for patients at high risk (chemoresistant, early relapse, and
extranodal disease) after autologous SCT.
13.1.2.CD25. CD25istheinterleukin-2receptorthatisover-
expressed on CHL cells. An 131I radio-immunoconjugate
(CHT-25) showed promising results in a phase I study on
12 CHL patients with single photon emission CT showing
tumour-speciﬁc uptake [87]. Of 9 patients treated with
>1200MBq/m2 3 achieved CR and 3 PR. Delayed myelotox-
icity was the most common adverse event with a platelet and
neutrophil nadir at 38 and 53 days, respectively.
Other surface markers being investigated as CHL selec-
tive targets include CD40, TRAIL, IL13 signalling, and CD
80.
13.2. Intracellular Signalling Pathways
13.2.1. Histone Deacetylase (HDAC) Inhibitors. Epigenetic
modiﬁcation ofgene expression is deranged in a wide variety
of malignancies, and histone deacetylase enzymes (HDACs)
are crucial mediators of this process. Small molecule class I12 Advances in Hematology
Table 10: Comparison of early phase studies of novel agents in relapsed and refractory Hodgkin’s lymphoma. Abbreviations: PR: partial
response;CR: complete response;ORR: overallresponserate; IL2-R:interleukin 2receptor; HDAC:histonedeacetylase; mTOR:mammalian
target of rapamycin.
Novel agent
(author) T a r g e t N o .o fP t s R o u t e P h a s e P R( % ) C R( % ) O R R( % )
SGN30
(Forero-Torres 2009) CD30 38 IV II 0 0 0
MDX060
(Ansell 2007) CD30 47 IV I/II 4 4 8
SGN35
(Younes 2008) CD30 44 IV I 14 25 39
SGN35
(Bartlett 2009) CD30 17 IV I 6 41 47
CHT25
(Dancey 2009)
IL2-R
radioimmunotherapy 9 IV I 33 33 66
MGCD0103
(Younes 2007) HDAC class I 21 Oral II 29 9 38
Panobinostat
(Dickinson 2009) Pan HDAC 13 Oral I/II 54 0 54
Panobinostat
(Younes 2009) Pan HDAC 27 Oral II 15 4 19
Vorinostat
(Kirschbaum 2007) Pan HDAC 25 Oral II 4 0 4
Everolimus
(Johnston) mTOR 19 Oral II 42 5 47
Bortezomib
(Younes 2006) Proteasome 14 IV II 7 0 7
Bortezomib
(Blum 2007) Proteasome 30 IV II 0 0 0
Rituximab
(Rehwald 2003) CD20 14 IV II 57 29 86
Rituximab
(Younes 2003) CD20 22 IV II 18 5 22
Lenalidomide
(Boll 2009) Immunomodulator 12 Oral II 23 8 50
Lenalidomide
(Kuruvilla) Immunomodulator 17 Oral II 47 6 53
and pan HDAC inhibitors have been developed, and phase
I trials in relapsed and refractory CHL have shown ORR of
between 4% and 54% with mild toxicity [88–91].
13.2.2. PI3K/Akt/mTOR. The PI3K/Akt/mTOR signalling
pathway is one of the most frequently deranged in all malig-
nancies. Phase II data on 19 CHL patients treated with the
mTOR inhibitor everolimus showed an ORR of 47% with
mild haematological toxicity [92]. The redundancy of many
intracellular signalling pathways suggests that combinations
of small molecule signalling modulators will be required to
improve eﬃcacy.
13.2.3. Anti-NFkB and Bortezomib. Another key signalling
molecule of CHL is the transcription factor NFkB, which
is constitutively activated in many lymphomas. Cytoplasmic
IkB usually inhibits NFkB from translocating to the nucleus
and upregulating multiple pro-proliferative genes. In CHL
various aberrant signalling pathways converge to cause IkB
to be degraded in the proteasome.
The feasibility of proteasome inhibitors to restore IkB
inhibition of NFkB has been demonstrated in preclinical
studies by Zheng et al. [93]. Proteasome inhibition in four
CHL cell lines demonstrated antiproliferative activity even
in the presence of mutated IkB or CD30, CD40 and RANK
receptor activation. Cytotoxic activity of gemcitabine was
also increased and bortezomib synergised with anti-CD30
antibody 5F11 in preclinical studies [94], however, no
signiﬁcant single-agent activity has been seen in early clinical
trailsinrelapsed HL[95,96].Itmaybethat bortezomib ﬁnds
a role either as a means of sensitising CHL cells to cytotoxic
agents or by synergising with other small moleculeinhibitors
of intracellular signalling.
13.2.4. HSP90. Other intracellular targets under investiga-
tion include the heat shock proteins such as HSP90.Advances in Hematology 13
13.3. Microenvironment/Immunotherapy. It has long been
noted that the majority of cells in CHL lymph nodes are
reactive. Hodgkin Reed-Sternberg (HRS) cells are diﬃcult
to grow in culture, and it has been postulated that they are
dependent on a supportive microenvironment to proliferate.
Therapeutic interventions to modify this interaction include
strategies to deplete supporting cells or modulate intercellu-
lar interactions.
13.3.1. Anti-CD20 (Rituximab). Promising early results have
been demonstrated with the anti-CD20 mAb rituximab,
despite CD20 being poorly expressed by HRS cells. Possible
mechanisms includealtering thenodalmicroenvironment or
direct targeting of a putative Hodgkin stem cell. 22 patients
(6 with CD20+ CHL) treated with rituximab at the MD
Anderson Center had an ORR of 22%, regardless of CD20
expression [97].
In a phase II study by the GHSG in CHL with more than
30% malignant cells expressing CD20 the ORR was as high
as 86% with 75% of responses durable at 1 year [98].
Adding rituximab to chemotherapy has been tested in
small studies. In combination with ABVD as ﬁrst-line treat-
ment 52 patients had an encouraging 3-year EFS and OS of
82% and 100% [99]. In the relapsed and refractory setting
adding rituximab to gemcitabine in 33 patients produced
a 48% ORR [100]. The GHSG HD18 trial is randomising
PET2-positive patients to either EB or R-EB, and we await
these results with interest.
13.3.2. Lenalidomide. Lenalidomide is a thalidomide ana-
loguewithanumberofimmunomodulatoryandantiangiog-
enic properties. It has been postulated to interfere with the
cancer-microenvironment interaction, and two studies in
relapsed CHL have shown ORRs of 50–53% despite some
signiﬁcant dose reductions [101, 102].
14.Conclusion
The current standard of care of CHL depends on disease
stage and risk. We believe that early favourable CHL should
be treated with 2 cycles of ABVD chemotherapy and 20Gy
IF RT according to the GHSG HD10 study. The results of
the EORTC H8U and GHSG HD8 studies establish 4 cycles
of ABVD-based chemotherapy followed by 36–40Gy IF RT
as the current standard of care in early stage unfavourable
CHL. 6–8 cycles of ABVD are the current standard in
advanced stage CHL, but we expect a rapidly increasing role
for BEACOPP-based regimens in high-risk cases guided by
interim PETresponses. Converselywe believetheuse oftoxic
agents such as bleomycin or radiotherapy will become more
restricted in lower-risk patients.
High-dose therapy with ASCT is the standard of care for
relapsed and refractory CHL. Every eﬀort should be made
to achieve chemosensitivity prior to transplant. With the
demonstration of a GvL eﬀect, RIC-alloSCT is a promising
area ofresearch that may beneﬁt carefully selected patients at
risk of recurrent relapse.
Hodgkin’s lymphoma research has resulted in major
advances in outcomes for patients by the targeted use of
eﬀective, standardised therapies employed according to reli-
able prognostic factors. Although CHL can be cured in the
majority of cases with conventional chemotherapy, further
improvements in eﬃcacy and reduction in toxicity will rely
on the development of the above and other promising
novel agents and their incorporation into individualised
combinations.
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